0

Ongoing Medicare Privatization Will Hurt Pharma As Much As the IRA

  The pharmaceutical industry is in a frenzy over the recently released list of the drugs subject to price negotiation under the Inflation Reduction Act of 2023 (IRA) and the Act’s potential impact on profits. But an even bigger force… Continue Reading

0

MArS Supplier Spotlight

Supplier Spotlight® highlights the unique skill sets and service offerings from organizations who are part of our CONNECTED COMMUNITY™. Below is an interview with Market Access & Pricing Strategy (MArS), the German-speaking market access experts. Tell us about MArS Market Access… Continue Reading

0

CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America

Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading

0

Drug Pricing Value Assessment Methods in the United States: The National Pharmaceutical Council Viewpoint

Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Drug prices are the fastest-growing part of healthcare costs, and everyone – from patients, to physicians, policy-makers, and pharmaceutical companies – are grappling with price-setting and drug value assessment.… Continue Reading